Business Description
Shattuck Labs Inc
NAICS : 541714
SIC : 2834
ISIN : US82024L1035
Share Class Description:
STTK: Ordinary SharesDescription
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 31.09 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 15.29 | |||||
| Beneish M-Score | -1.07 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -60.7 | |||||
| 3-Year EBITDA Growth Rate | 4.1 | |||||
| 3-Year EPS without NRI Growth Rate | 4.6 | |||||
| 3-Year FCF Growth Rate | 4.8 | |||||
| 3-Year Book Growth Rate | -25.5 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 74.3 | |||||
| 9-Day RSI | 66.81 | |||||
| 14-Day RSI | 62.53 | |||||
| 6-1 Month Momentum % | 431.53 | |||||
| 12-1 Month Momentum % | 205.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.51 | |||||
| Quick Ratio | 12.51 | |||||
| Cash Ratio | 11.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.2 | |||||
| Shareholder Yield % | 0.08 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -5549.61 | |||||
| Net Margin % | -5268.44 | |||||
| FCF Margin % | -4926.67 | |||||
| ROE % | -59.81 | |||||
| ROA % | -52.7 | |||||
| ROIC % | -345.89 | |||||
| ROC (Joel Greenblatt) % | -486.67 | |||||
| ROCE % | -61.4 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 259.55 | |||||
| PB Ratio | 3.46 | |||||
| Price-to-Tangible-Book | 3.46 | |||||
| EV-to-EBIT | -3.68 | |||||
| EV-to-Forward-EBIT | -3.61 | |||||
| EV-to-EBITDA | -3.85 | |||||
| EV-to-Forward-EBITDA | -3.61 | |||||
| EV-to-Revenue | 204.36 | |||||
| EV-to-Forward-Revenue | 282.19 | |||||
| EV-to-FCF | -4.15 | |||||
| Price-to-Net-Current-Asset-Value | 3.89 | |||||
| Price-to-Net-Cash | 4.32 | |||||
| Earnings Yield (Greenblatt) % | -27.17 | |||||
| FCF Yield % | -16.21 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers